Novo Nordisk will slash U.S. list prices of its blockbuster diabetes and weight-loss drugs Ozempic and Wegovy by up to 50% starting next year, the Danish drugmaker said on Tuesday. Ciara Lee reports.

The following are the ​top stories in the Financial ​Times. Reuters has ‌not verified ​these stories and does not vouch for their accuracy.

Eli Lilly alum Ramesh Durvasula joined Roche as its chief data officer. Derrick Gastineau joined Novo Nordisk as U.S. brand leader for the oral version of Wegovy and Cagrisema.

Demand from patients for obesity medication is unrelenting. So, too, is the battle over who gets to develop and distribute the treatments.

Since 2023, Eli Lilly and Co. has filed lawsuits against dozens of compound pharmacies, weight-loss centers and health spas that produced and sold copies of Mounjaro and Zepbound.

President Trump has a tricky line to walk tonight during the first State of the Union address of his second term. This is his ...

A once-daily experimental GLP-1 pill shows greater weight loss and blood sugar control than current oral options, and could soon reshape obesity and diabetes care.

The U.S. Food and Drug Administration (FDA) will take swift action against companies that mass-market "illegal copycat drugs" by claiming they are similar to FDA-approved products, its commissioner, ...

Tech shares bounced on Tuesday following the prior session's selloff as markets weigh the impact of artificial intelligence ...

European and US stocks bounced higher as investors recovered from a fresh bout of angst over AI and new US tariffs.

The FDA approves the Allurion balloon for weight loss, which is swallowed and doesn't require a procedure for removal. Doctors explain how it works.

TIME reveals the third annual TIME100 Health list, recognizing the 100 most influential individuals in health.